poisar

Stocks · News reference

MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate

Benzinga Newsdesk

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of $(1.06) per share

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

INKT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Insights

    MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript

    MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to

    INKT